

Remarks

Currently Claims 1-7, 10-12 and 17-25 are pending. Claims 8-9 and 13-16 are canceled. Claims 1, 3-5, 7 and 10-12 are amended herein. Claim 1 is amended to change plural to singular. Claims 1 and 5 are amended to change "represents" to "is." Claim 5 is amended to remove recitation of the narrower species indicated by "e.g.," which is now the subject of new claim 17. Claims 3-5, 7 and 10-12 are amended to remove multiple dependencies for the purpose of reducing claim fees. Claims 7 and 10-12 are further amended to remove the duplicative recitation "and pharmaceutically acceptable derivatives thereof" inasmuch as that recitation appears in claim 1 from which claims 7 and 10-12 depend. The amendments do not narrow the scope of the claims and are not being made for reasons of patentability. No new matter is added.

New claims 17-28 are added. Support for new claim 17 can be found in Applicants' original specification including at original claim 5. Support for new claim 18 can be found in Applicants original specification, including at page 17, line 32. Support for new claims 19-25 can be found in Applicants original specification including at Example 29, page 17, line 32, and original claims 10-12. No new matter is added.

The specification has been amended to recite related applications and to provide an abstract on a separate page. No new matter is added.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

^{22 Sep}
Date: ~~6 August~~, 2004
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
Lorie.A.Morgan@gsk.com